Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. (CATX) trades at $2.64 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, CATX trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Sep 15, 2026.